New pill may help myeloma patients stay in remission longer after transplant
NCT ID NCT05177536
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called iberdomide as maintenance therapy for people with multiple myeloma who have had a stem cell transplant. The goal is to see if more patients can stay on treatment for at least a year without the disease getting worse. About 40 adults will take iberdomide pills for 21 days each month, and researchers will monitor how well they tolerate it and how long they remain cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iberdomide (a pill that helps the immune system attack cancer cells)
What this could lead to
If successful, this could offer a better-tolerated maintenance option for multiple myeloma patients after stem cell transplant, potentially reducing relapse.
What could go wrong
This is a small, early-phase study with only 40 participants. It may not show clear benefit, and iberdomide could still cause side effects or fail to prevent relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States